You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 217729


✉ Email this page to a colleague

« Back to Dashboard


NDA 217729 describes BOSULIF, which is a drug marketed by Pf Prism Cv and is included in two NDAs. It is available from two suppliers. There are five patents protecting this drug and two Paragraph IV challenges. Additional details are available on the BOSULIF profile page.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
Summary for 217729
Tradename:BOSULIF
Applicant:Pf Prism Cv
Ingredient:bosutinib monohydrate
Patents:5
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217729
Generic Entry Date for 217729*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 217729
Suppliers and Packaging for NDA: 217729
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BOSULIF bosutinib monohydrate CAPSULE;ORAL 217729 NDA Pfizer Laboratories Div Pfizer Inc 0069-0504 0069-0504-30 30 CAPSULE in 1 BOTTLE (0069-0504-30)
BOSULIF bosutinib monohydrate CAPSULE;ORAL 217729 NDA Pfizer Laboratories Div Pfizer Inc 0069-1014 0069-1014-15 150 CAPSULE in 1 BOTTLE (0069-1014-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 50MG BASE
Approval Date:Sep 26, 2023TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 26, 2026
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Mar 26, 2027
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Regulatory Exclusivity Expiration:Mar 26, 2031
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.